Low-dose HDAC inhibitors, trichostatin-A (TSA) and CG-745, modify the tumor immune microenvironment by reducing TAM suppressive activity and MDSC recruitment, thereby enhancing immunotherapy effectiveness [201, 202]. Here, HDAC9 is linked to neoplasm.